Eli Lilly has finalized a deal to acquire Houston-based startup CrossBridge Bio, marking its latest investment in the rapidly evolving antibody-drug conjugate (ADC) sector. The transaction, valued at up to $300 million, underscores Lilly’s commitment to securing next-generation precision oncology technologies.
Deal Overview and Technological Significance:
-
Financial Structure: The buyout is an all-cash transaction comprising an upfront payment and subsequent milestones linked to developmental progress.
-
Dual-Payload Innovation: Unlike conventional ADCs that deliver a single cytotoxic agent, CrossBridge Bio’s platform focuses on “dual-payload” therapies. This approach equips antibodies with two distinct toxic warheads, designed to deliver a more potent and precise blow to malignant cells.
-
Lead Candidate (CBB-120): The acquisition centers on CBB-120, a TROP2-targeted ADC. The company claims this candidate offers a wider therapeutic index and superior ability to overcome treatment resistance compared to existing TROP2-directed therapies currently on the market.
For Lilly, this move follows a string of ADC-related acquisitions, including Emergence Therapeutics and Mablink Bioscience in 2023. By incorporating CrossBridge’s platform, Lilly aims to enhance its oncology pipeline as the industry increasingly looks toward ADCs to replace traditional chemotherapy. CBB-120 is expected to enter human clinical trials later this year.